Skip to Content

Cyclo Therapeutics Inc CYTH

Morningstar Rating
$1.40 +0.03 (2.19%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CYTH is trading at a 689% premium.
Price
$1.40
Fair Value
$7.34
Uncertainty
Extreme
1-Star Price
$54.00
5-Star Price
$2.95
Economic Moat
Vrzvj
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CYTH is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$1.37
Day Range
$1.331.40
52-Week Range
$0.892.57
Bid/Ask
$1.25 / $1.54
Market Cap
$40.20 Mil
Volume/Avg
21,599 / 93,115

Key Statistics

Price/Earnings (Normalized)
Price/Sales
25.76
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Value
Total Number of Employees
8

Valuation

Metric
CYTH
Price/Earnings (Normalized)
Price/Book Value
65.67
Price/Sales
25.76
Price/Cash Flow
Price/Earnings
CYTH

Financial Strength

Metric
CYTH
Quick Ratio
0.47
Current Ratio
1.01
Interest Coverage
Quick Ratio
CYTH

Profitability

Metric
CYTH
Return on Assets (Normalized)
−267.11%
Return on Equity (Normalized)
−3,882.43%
Return on Invested Capital (Normalized)
−2,190.61%
Return on Assets
CYTH
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ZTS
Zoetis Inc Class AThcrghylsWjps$79.4 Bil
MKKGY
Merck KGaA ADRDdxjlnxdTftmpq$79.0 Bil
HLN
Haleon PLC ADRGcthcnvbXdhg$38.5 Bil
VTRS
Viatris IncVryyzhgdMjbf$13.1 Bil
RDY
Dr Reddy's Laboratories Ltd ADRHjfhhvhtWkzmq$11.7 Bil
CTLT
Catalent IncSnnxvdmGqpmgw$10.0 Bil
CURLF
Curaleaf Holdings IncYgzdkkhXyh$4.2 Bil
PRGO
Perrigo Co PLCBkhzthfgsHhvp$4.1 Bil
PBH
Prestige Consumer Healthcare IncPkmgmlgnCfrzt$3.2 Bil
GTBIF
Green Thumb Industries IncByskptzwmNzzl$3.1 Bil

Sponsor Center